In a notable leap forward for medical science, MIT researchers have utilized artificial intelligence to create pioneering antibiotics targeting stubborn infections like drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA), according to MIT News. This breakthrough arrives as an urgent response to the escalating threat of bacterial resistance which causes nearly 5 million deaths worldwide annually.
Fueled by generative AI algorithms, the team synthesized over 36 million potential compounds, diving deep into the uncharted territories of chemical structures and distinguishing their discoveries from any current antibiotics as these novel candidates seem to introduce fresh mechanisms that disrupt bacteria cell membranes, which is a significant development because the ongoing medical challenge posed by such bacteria has been fraught with complications, due to the organisms' ability to quickly adapt and thwart existing antibiotic treatments. "We're excited about the new possibilities that this project opens up for antibiotics development," James Collins, the Termeer Professor of Medical Engineering and Science at MIT's Institute for Medical Engineering and Science, told MIT News.
The study, led by postdocs and doctoral students at MIT, employed a dual-pronged approach: pinpointing molecules based on a specific antimicrobial fragment, and allowing AI to freely generate molecules without constraints. Through their rigorous screening process, the researchers were able to narrow millions of candidates down to a single compound, NG1, which proved highly effective against gonorrhea in both lab and mouse models by interfering with a protein essential to bacterial outer membrane synthesis, thus showcasing a previously unexploited method of antibacterial attack.
In their pursuit against S. aureus, the team used their generative AI models to produce additional millions of compounds subsequently filtered to identify a handful with potent antibacterial properties, and among them, DN1 demonstrated the capability to clear MRSA infections in mice, its mode of action is broad, affecting the bacterial cell membranes across a wider spectrum unlike NG1 which targets a specific protein, thus expanding the potential use cases for these new antibiotics beyond traditional approaches, which is a crucial development given the rapid rise in resistance to available drug treatments.
